SOOD NITIN
Known title: Chief Commercial OfficerCIK: 0001877433
Associated companies
Transaction History
| ADPT | ▼ Sell | Open Market | 10,550 | $69K | 8/8/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 5,652 | $38K | 8/7/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 9,813 | $84K | 3/7/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 6,661 | $57K | 3/6/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 132,979 | $0 | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 31,066 | $249K | 11/1/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 17,540 | $193K | 8/5/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 65,898 | $0 | 3/4/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 97,213 | $0 | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.